Primary aldosteronism
Conditions
Interventions
None listed
Sponsors
Kanazawa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients who considered surgical treatment for primary aldosteronism The patients that written informed consent was obtained
Exclusion criteria
Exclusion criteria: 1) The PA patients who do not hope for surgery 2) The patients who are taking spcific drugs (including the steroid) which affect a plasma aldosterone concentration and a plasma cortisol concentration 3) the patients with allergy for a natural rubber, cosyntropin and the iodocontrast media 4) The patients with unstable angina 5) The patients with the serious hepatic disorder (AST(GOT) or ALT (GPT) more than 100IU/L) 6) The patients with the pregnant or pregnant likelihood 7) The patients who are treated with malignant disorder except for the adrenal cancer 8) The patients with severe renal dysfunction (eGFR <20mL/min/1.73m2) 9) The patients who participated in other clinical trials within three months before AVS 10) The patients who were judged to be inadequate as study patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the clinical sensitivity and clinical specificity of the new quick cortisol assay kit, and to assess the correlation in comparison with conventional cortisol assay | — |
Secondary
| Measure | Time frame |
|---|---|
| QCA measurement time Repetition measurement rate of the QCA measurement Complete failure rate of the QCA measurement | — |
Countries
Japan
Contacts
Public ContactMitsuhiro Kometani
Kanazawa University Hospital Division of Endocrinology and Metabolism
Outcome results
None listed